A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
NCT06897930
This study is recruiting at 10 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus Erythematosus.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Lupus Erythematosus, Systemic
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- AstraZeneca
- Last updated on ClinicalTrials.gov
- September 10, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Research Site · San Francisco, CA
Georgia · 1
- Research Site · Atlanta, GA
Massachusetts · 1
- Research Site · Boston, MA
Missouri · 1
- Research Site · St Louis, MO
New York · 2
- Research Site · New York, NY
- Research Site · Syracuse, NY
North Carolina · 2
- Research Site · Chapel Hill, NC
- Research Site · Charlotte, NC
Washington · 2
- Research Site · Seattle, WA
- Research Site · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.